Nope...a much higher dosing is referenced in a pat

Quote:

---

Nope...a much higher dosing is referenced in a patent

---

Patents are filed long before the drug is ever used in a patient and is an estimate of tolerability. We already get site reactions with two 350mg doses. Part of that is leronlimab itself and part would be the volume of fluid injected. The second problem with something as high as 1800mg might be an increased antibody level against leronlimab that could reduce the amount of available leronlimab. A better solution would be first injection at 700mg and a 350mg injection 4 days after. Cytodyn would have to test that for safety and efficacy of course.